$10.49
0.00%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US18507C1036
Symbol
CLPT

ClearPoint Neuro Stock price

$10.49
-0.06 0.57% 1M
-4.03 27.75% 6M
-4.89 31.79% YTD
-2.69 20.41% 1Y
-2.34 18.24% 3Y
+6.10 138.95% 5Y
+9.83 1,489.39% 10Y
+9.74 1,298.67% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.00 0.00%
ISIN
US18507C1036
Symbol
CLPT

Key metrics

Basic
Market capitalization
$298.2m
Enterprise Value
$285.5m
Net debt
positive
Cash
$41.5m
Shares outstanding
28.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.9 | 7.8
EV/Sales
8.5 | 7.4
EV/FCF
negative
P/B
15.1
Financial Health
Equity Ratio
64.8%
Return on Equity
-74.5%
ROCE
-40.8%
ROIC
-123.0%
Debt/Equity
1.5
Financials (TTM | estimate)
Revenue
$33.6m | $38.4m
EBITDA
$-21.6m | $-13.2m
EBIT
$-22.6m | $-22.8m
Net Income
$-22.2m | $-23.3m
Free Cash Flow
$-11.7m
Growth (TTM | estimate)
Revenue
19.7% | 22.3%
EBITDA
-21.7% | 29.9%
EBIT
-21.8% | -15.4%
Net Income
-23.6% | -23.4%
Free Cash Flow
-18.5%
Margin (TTM | estimate)
Gross
60.4%
EBITDA
-64.4% | -34.3%
EBIT
-67.3%
Net
-66.2% | -60.8%
Free Cash Flow
-34.9%
More
EPS
$-0.8
FCF per Share
$-0.4
Short interest
9.3%
Employees
115
Rev per Employee
$270.0k
Show more

Is ClearPoint Neuro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

ClearPoint Neuro Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ClearPoint Neuro forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a ClearPoint Neuro forecast:

Buy
88%
Hold
13%

Financial data from ClearPoint Neuro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
34 34
20% 20%
100%
- Direct Costs 13 13
18% 18%
40%
20 20
21% 21%
60%
- Selling and Administrative Expenses 29 29
18% 18%
87%
- Research and Development Expense 14 14
28% 28%
41%
-22 -22
22% 22%
-64%
- Depreciation and Amortization 1 1
23% 23%
3%
EBIT (Operating Income) EBIT -23 -23
22% 22%
-67%
Net Profit -22 -22
24% 24%
-66%

In millions USD.

Don't miss a Thing! We will send you all news about ClearPoint Neuro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ClearPoint Neuro Stock News

Positive
Seeking Alpha
17 days ago
ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, particularly uniQure's Huntington's therapy. Positive partner data and strong system placements could drive ClearPoint's stock higher in 2025.
Neutral
Seeking Alpha
19 days ago
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Operator Greet...
Neutral
Accesswire
20 days ago
Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2025.
More ClearPoint Neuro News

Company Profile

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Head office United States
CEO Joseph Burnett
Employees 115
Founded 1998
Website www.clearpointneuro.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today